Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies

Clinical Cancer Research

Volumn 3, Issue 3, 1997, Pages 409-417

  Atkins, Michael B ^a   Robertson, Michael J ^b   Gordon, Michael ^c   Lotze, Michael T ^d   DeCoste, Michelle ^e   DuBois, Jon S ^a   Ritz, Jerome ^b   Sandler, Alan B ^c   Edington, Howard D ^d   Garzone, Pamela D ^e   Mier, James W ^a   Canning, Christine M ^b   Battiato, Linda ^c   Tahara, Hideaki ^d   Sherman, Matthew L ^e  

^a TUFTS MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c INDIANA UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 12;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; DRUG EFFICACY; FEMALE; HUMAN; HYPERBILIRUBINEMIA; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CANCER; LIVER TOXICITY; LYMPHOCYTOPENIA; MALE; MELANOMA; MULTICENTER STUDY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERGLYCEMIA; INJECTIONS, INTRAVENOUS; INTERLEUKIN-12; LIVER; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; RECOMBINANT PROTEINS;

EID: 0030887047     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Kobayashi, M., Fitz, L., Ryan, M., Hewick, R. M., Clark, S. C., Chan, S., Loudon, R., Sherman, F., Perussia, B., and Trinchieri, G. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med., 170: 827-845, 1989.
2. Stem, A. S., Podlaski, F. J., Hulmes, J. D., Pan, Y-C. E., Quinn, P. M., Wolitzky, A. G., Familletti, P. C., Stremlo, D. L. Truitt, T., Chizzonite, R., and Gately, M. K. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc. Natl. Acad. Sci. USA, 87: 6808-6812, 1990.
3. Wolf, S. F., Temple, P. A., Kobayashi, M., Young, D., Dicig, M., Lowe, L., Dzialo, R., Fitz, L., Ferenz, C., Hewick, R. M., Kelleher, K., Herrmann, S. H., Clark, S. C., Azzoni, L., Chan, S. H., Trinchieri, G., and Perussia, B. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J. Immunol., 146: 3074-3081, 1991.
4. Sieburth, D., Jabs, E. W., Warrington, J. A., Li, X., Lasota, J., LaForgia, S., Kelleher, K., Huebner, K., Wasmuth, J. J., and Wolf, S. F. Assignment of genes encoding a unique cytokine (IL-IL-12) composed of two unrelated subunits to chromosomes 3 and 5. Genomics, 14: 59-62, 1992.
5. Merberg, D. M., Wolf, S. F., and Clark, S. C. Sequence similarity between NKSF and the IL6/G-CSF family. Immunol. Today, 13: 77-78, 1992.
6. Gearing, D. P., and Cosman, D. Homology of the p40 subunit of natural killer cell stimulatory factor (NKSF) with the extra cellular domain of the interleukin-6 receptor. Cell, 66: 9-10, 1991.
7. D'Andrea, A., Rengaraju, M., Valiante, N. M., Chehimi, J., Kubin, M., Aste, M., Chan, S. H., Kobayashi, M., Young, D., Nickbarg, E., Chizzonite, R., Wolf, S. F., and Trinchieri, G. Production of natural killer cell stimulatory factors (interleukin-12) by peripheral blood mononuclear cells. J. Exp. Med., 176: 1387-1398, 1992.
8. Chua, A. O., Chizzonite, R., Bhupesh, B. D., Truitt, T. P., Nunes, P., Minetti, L. J., Warrier, R. R., Presky, D. H., Levine, J. F., Gately, M. K., and Gubler, U. Expression cloning a human IL-12 receptor component: a new member of the cytokine receptor superfamily with strong homology to gp130. J. Immunol., 153: 128-136, 1994.
9. Chizzonite, R., Truitt, T., Desai, B. B., Nunes, P., Podlaski, F. J., Stern, A. S., and Gately, M. K. IL-12 receptor. I. Characterization of the receptor on phytohemagglutinin-activated human lymphoblasts. J. Immunol., 148: 3117-3124, 1992.
10. Desai, B. B., Quinn, P. M., Wolitzky, A. G., Mongini, P. K. A., Chizzonite, R., and Gately, M. K. IL-12 receptor. II. Distribution and regulation of receptor expression. J. Immunol., 148: 3125-3132, 1992.
11. Metzger, D. W., Vogel, L. A., Van Cleave, V. H., Lester, T. L., and Buchanan, J. M. The effects of IL-12 on B-cell subset function. Res. Immunol., 146: 499-505, 1995.
12. Robertson, M. J., Soiffer, R. J., Wolf, S. F., Manley, T. J., Donauhue, C, Young, D., Hermann, S. H., and Ritz, J. Responses of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J. Exp. Med., 175: 779-788, 1992.
13. Naume, B., Gately, M., and Expevi, T. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor), IL-2, and IL-7 induced effects on immunomagnetically purified CD56+ NK cells. J. Immunol., 143: 127-142, 1992.
14. Gately, M. K., Wolitzky, A. G., Quinn, P. M., and Chizzonite, R. Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell. Immunol., 143: 127-142, 1992.
15. Gately, M. K., Desai, B. B., Wolitzky, A. G., Quinn, P. M., Dwyer, C. M., Podlaski, F. J., Familletti, P. C., Sinigaglia, F., Chizzonite, R., Gubler, U., and Stem, A. S. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotic lymphocyte maturation factor). J. Immunol., 147: 874-882, 1991.
16. Perussia, B., Chan, S. H., D'Andrea, A., Tsuji, K., Santoli, D., Pospisil, M., Young, D., Wolf, S. F., and Trinchieri, G. Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-αβ+, TCR-γδ+ T lymphocytes, and NK cells. J. Immunol., 149: 3495-3502, 1992.
17. Bertagnolli, M. M., Lin, B-Y., Young, D., and Herrmann, S. H. IL-12 augments antigen-dependent proliferation of activated T lymphocytes. J. Immunol., 149: 3778-3783, 1992.
18. Chan, S. H., Kobayashi, M., Santoli, D., Perussia, B., and Trinchieri, G. Mechanisms of IFN-γ induction by natural killer cell stimulatory factor (NKSF/IL-12). Role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2. J. Immunol., 148: 92-98, 1992.
19. Mier, J., Vachino, G., Van der Meer, J., Numerof, R., Adams, S., Cannon, J., Bernheim, H., Atkins, M., Parkinson, D., and Dinarello, C. Induction of circulating tumor necrosis factor (TNF) as the mechanism for the febrile response to Interleukin-2 (IL-2) in cancer patients. J. Clin. Immunol., 8: 426-436, 1988.
20. H1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med., 177: 1199-1204, 1993.
21. Scott, P. IL-12: initial cytokine for cell-mediate immunity. Science (Washington DC), 260: 496-497, 1993.
22. H1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science (Washington DC), 260: 547-549, 1993.
23. Gazzinelli, R. T., Hieny, S., Wynn, T. A., Wolf, S. F., and Sher, A. Interleukin 12 is required for the T-lymphocyte independent induction of Interferon γ by an intra-cellular parasite and induces resistance in T-cell deficient hosts. Proc. Natl. Acad. Sci. USA, 90: 6115-6119, 1993.
24. Sypek, J. P., Chung, C. L., Mayor, S. E. H., Subramanyam, J. M., Goldman, S. J., Sieburth, D. S., Wolf, S. F., and Schaub, R. G. Resolution of cutaneous leishmaniasis: interleukin-12 initiates a protective T helper type 1 immune response. J. Exp. Med., 177: 1797-1802, 1993.
25. Afonso, L. C. C., Scharton, T. M., Vieira, L. Q., Wysocka, M., Trinchieri, G., and Scott, P. IL-12 functions as an effective adjuvant in a vaccine against Leishmania major by directing the development of leishmanial specific CD4+ Th1 cells. Science (Washington DC), 263: 235-237, 1994.
26. Brunda, M. J., Luistro, L., Warner, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F., and Gately, M. K. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J. Exp. Med., 178: 1223-1230, 1993.
27. Nastala, C. L., Edington, H. D., McKinney, T. G., Tahara, H., Nalesnik, M. A., Brunda, M. J., Gately, M. K., Wolf, S. F., Schreiber, R. D., Storkus, W. J., and Lotze, M. T. Recombinant IL-12 administration induces tumor regression in association with IFN Gamma production. J. Immunol., 153: 1697-1706, 1994.
28. Murray, K. S., Garzone, P., Wiencis, A. M., Kolowsky, M. L., Velickovic, A., Celniker, A., and Van Cleave, V. H. Chemiluminescent-based ELISA for IL-12: high sensitivity permits pharmacokinetic analysis. Abstract of the Ninth International Congress of Immunology, p. 23, 1995.
29. Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., and Carbone, P. P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol., 5: 649-655, 1982.
30. Dinarello, C. A., Cannon, J. G., Mier, J. W., Bernheim, H. A., Lo-Preste, G., Lynn, D. L., Love, R. N., Webb, A. C., Auron, P. E., Reuben, R. C., Rich, A., Wolff, S. M., and Putney, S. D. Multiple biological activities of human recombinant imerleukin-1. J. Clin. Invest., 77: 1734-1739, 1986.
31. Atkins, M. B., Gould, J. A., Allegretta, M., Li, J. J., Dempsey, R. A., Rudders, R. A., Parkinson, D. R., Reichlin, S., and Mier J. W. Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease. J. Clin. Oncol., 4: 1380-1391, 1986.
32. Atkins, M. B., Vachino, G., Tilg, H. J., Kappler, K., Karp, D. D., Robert, N. J., and Mier, J. W. Phase I evaluation of thrice daily intravenous bolus Interleukin-4 (IL-4) in patients with refractory malignancy. J. Clin. Oncol., 10: 1802, 1992.
33. Weber, J., Yang, J. C., Topalian, S. L., Parkinson, D. R., Schwartzentruber, D. S., Ettinghausen, S. E., Gunn, H., Mixon, A., Kim, H., Cole, D., Levin, R., and Rosenberg, S. A. A phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J. Clin. Oncol., 11: 449, 1993.
34. Sosman, J. A., Aronson, F. R., Sznol, M., Atkins, M. B., Dutcher, J. P., Fisher, R. I., Weiss, G. R., Isaacs, R. E., Margolin, K. A., Ernest, M. L., Mier, J. W., Oleksowicz, L., Eckhardt, J. R., Levitt, D., and Doroshaw, J. H. Interleukin-6: Phase I trials of 1 and 120 h intravenous infusions. Proc. Am. Soc. Clin. Oncol., 12: 292, 1993.
35. Quesada, J. R. Biologic therapy with interferon-γ. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Biologic Therapy of Cancer, pp. 435-442. Philadelphia: J. B. Lippincott Co., 1995.
36. Neta, R., Stiefel, S. M., Finkelman, F., Herrmann, S., and Ali, N. IL-12 protects bone marrow from and sensitizes intestinal tract to ionizing radiation. J. Immunol., 153: 4230-4237, 1994.
37. Planchon, S. M., Martins, C. A. P., Guerrant, R. L., and Roche, J. K. Regulation of intestinal epithelial barrier function by TGF-β1: evidence for its role in abrogating the effect of a T cell cytokine. J. Immunol., 153: 5730-5739, 1994.
38. Cohen, J. IL-12 deaths: explanation and a puzzle. Science (Washington DC), 270: 908, 1995.